
AZENTA INC
AZTANASDAQTrading Snapshot
- Day Range
- $32.85 โ $33.59
- 52-Week Range
- $15.93 โ $41.73
- Volume
- $5.04B
- Avg Volume
- $4.38B
- Shares Outstanding
- 46.1M
- Next Earnings
- Sep 21, 2026
Fundamentals Snapshot
- Annual Revenue
- $594M
- Last Q Revenue
- $161M
- P/E Ratio
- -12.1
- P/S Ratio
- 2.5x
- EPS (TTM)
- $-2.71
- Dividend Yield
- 0.00%
Why Investors Own AZTA
- โHigh-growth profile โ revenue up +19.0% YoY with expanding US Equity exposure.
- โHealthy economics โ 44% gross margin and 15% free-cash-flow margin.
- โNew products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
About AZENTA INC
Azenta, Inc. is a global leader specializing in advanced solutions for the discovery, handling, and preservation of life science samples. The company's operations span across North America, Europe, Asia Pacific (including China), and other international markets. Its business is structured into two main reportable segments: Life Sciences Products and Life Sciences Services. The Life Sciences Products division supplies sophisticated automated systems for the cold storage of chemical compounds and biological specimens. This segment also provides crucial equipment for sample preparation and manipulation, along with various consumables and specialized instruments that empower customers to effectively manage samples throughout their entire research and development workflows. Conversely, the Life Sciences Services segment offers a comprehensive suite of programs for sample management, integrated cold chain logistics, cutting-edge informatics, and a range of sample-centric laboratory services. These offerings are vital for propelling scientific research and accelerating drug development. Key services include secure sample banking, advanced genomic sequencing, gene synthesis, laboratory processing, detailed laboratory analysis, biospecimen acquisition, and other essential support functions. Azenta caters to a diverse client base within the life sciences sector, encompassing pharmaceutical companies, biotechnology firms, biorepositories, and academic or private research institutions. Established in 1978, the company, originally known as Brooks Automation, Inc., officially became Azenta, Inc. in December 2021. Its corporate headquarters are located in Chelmsford, Massachusetts.
Otter Score Breakdown
โAnalyst Ratings
โLatest News & Updates
Evercore ISI Group Maintains Outperform on Azenta, Raises Price Target to $35
Evercore ISI Group analyst Vijay Kumar maintains Azenta (NASDAQ:AZTA) with a Outperform and raises the price target from $28 to $35.
Needham Maintains Buy on Azenta, Raises Price Target to $37
Needham analyst David Saxon maintains Azenta (NASDAQ:AZTA) with a Buy and raises the price target from $33 to $37.

Azenta, Inc. (AZTA) Q3 2026 Earnings Call Transcript
Azenta, Inc. (AZTA) Q3 2026 Earnings Call August 5, 2026 8:30 AM EDTCompany ParticipantsYvonne Perron - Vice President of Financial Planning & Analysis...

Azenta, Inc. 2026 Q3 - Results - Earnings Call Presentation
2026-08-05. The following slide deck was published by Azenta, Inc.
Azenta Narrows FY2026 Sales Guidance from $603.000M-$621.000M to $613.000M-$618.000M vs $600.458M Est
Azenta (NASDAQ:AZTA) narrows FY2026 sales outlook from $603.000 million-$621.000 million to $613.000 million-$618.000 million vs $600.458 million estimate.
Azenta Q3 Adj. EPS $0.16 Beats $0.11 Estimate, Sales $161.000M Beat $149.288M Estimate
Azenta (NASDAQ:AZTA) reported quarterly earnings of $0.16 per share which beat the analyst consensus estimate of $0.11 by 45.45 percent. This is a 15.79 percent decrease over earnings of $0.19 per share from the same